Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Oct 1;1(7):1111-1134.

2.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Oct 1;2(10):e25771. Epub 2013 Jul 29. Review.

3.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
4.

Trial watch: Dendritic cell-based anticancer therapy.

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 21;3(11):e963424. eCollection 2014 Nov. Review.

5.
6.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Gardner TA, Elzey BD, Hahn NM.

Hum Vaccin Immunother. 2012 Apr;8(4):534-9. doi: 10.4161/hv.19795. Review.

PMID:
22832254
7.

Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.

Ragde H, Cavanagh WA, Tjoa BA.

J Urol. 2004 Dec;172(6 Pt 2):2532-8. Review.

PMID:
15538202
8.
9.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK.

J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.

PMID:
25839441
10.

Personalized dendritic cell-based tumor immunotherapy.

Janikashvili N, Larmonier N, Katsanis E.

Immunotherapy. 2010 Jan;2(1):57-68. Review.

11.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
12.

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S.

Cancer Immunol Immunother. 2006 Dec;55(12):1524-33. Epub 2006 Apr 13.

PMID:
16612599
13.

Therapeutic dendritic cell-based cancer vaccines: the state of the art.

Strioga MM, Felzmann T, Powell DJ Jr, Ostapenko V, Dobrovolskiene NT, Matuskova M, Michalek J, Schijns VE.

Crit Rev Immunol. 2013;33(6):489-547. Review.

PMID:
24266347
14.

DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.

Cao J, Jin Y, Li W, Zhang B, He Y, Liu H, Xia N, Wei H, Yan J.

BMC Immunol. 2013 Aug 14;14:39. doi: 10.1186/1471-2172-14-39.

15.

Potential approaches for more successful dendritic cell-based immunotherapy.

Chiang CL, Balint K, Coukos G, Kandalaft LE.

Expert Opin Biol Ther. 2015 Apr;15(4):569-82. doi: 10.1517/14712598.2015.1000298. Epub 2015 Jan 2. Review.

PMID:
25553913
16.

Dendritic cell-based treatment of cancer: closing in on a cellular therapy.

Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R.

Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61.

PMID:
11777265
17.

Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery.

Xiao L, Hung KC, Takahashi TT, Joo KI, Lim M, Roberts RW, Wang P.

ACS Chem Biol. 2013 May 17;8(5):967-77. doi: 10.1021/cb300680c. Epub 2013 Mar 8.

PMID:
23427768
18.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

19.
20.

Supplemental Content

Support Center